Axon Enterprise (NASDAQ:AXON) President Sells $6,349,850.00 in Stock

Axon Enterprise, Inc (NASDAQ:AXON) President Joshua Isner sold 13,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $488.45, for a total value of $6,349,850.00. Following the transaction, the president directly owned 169,125 shares in the company, valued at approximately $82,609,106.25. The trade was a 7.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock traded down $15.06 during trading on Monday, hitting $471.06. 944,826 shares of the company’s stock traded hands, compared to its average volume of 1,098,237. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91. The business has a 50-day simple moving average of $408.04 and a 200-day simple moving average of $491.56. The stock has a market capitalization of $37.97 billion, a P/E ratio of 189.18, a PEG ratio of 8.84 and a beta of 1.45. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The business had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.During the same quarter in the previous year, the firm earned $1.47 EPS. Axon Enterprise’s revenue was up 33.7% on a year-over-year basis. As a group, analysts forecast that Axon Enterprise, Inc will post 1.82 EPS for the current year.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of research analyst reports. TD Cowen cut their target price on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a research report on Wednesday, April 8th. Wall Street Zen upgraded shares of Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. JPMorgan Chase & Co. boosted their target price on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. The Goldman Sachs Group set a $535.00 target price on shares of Axon Enterprise in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada reduced their price objective on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently made changes to their positions in AXON. Brighton Jones LLC bought a new stake in Axon Enterprise during the fourth quarter worth approximately $480,000. NewEdge Advisors LLC boosted its holdings in shares of Axon Enterprise by 41.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after purchasing an additional 668 shares during the period. Empowered Funds LLC increased its position in shares of Axon Enterprise by 8.4% during the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after purchasing an additional 157 shares during the last quarter. Woodline Partners LP increased its position in shares of Axon Enterprise by 40.6% during the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after purchasing an additional 2,003 shares during the last quarter. Finally, Sivia Capital Partners LLC purchased a new stake in Axon Enterprise during the 2nd quarter valued at $284,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.